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As an example of (1) above, a patient on whom I had 
performed bilateral carotid endarterectomies 8 years pre- 
viously was admitted with multiple episodes of amaurosis 
fugax in the eye appropriate o an occluded external carotid 
artery, although that internal carotid artery and the 
contralateral carotid system were widely patent on angiog- 
raphy. Operation consisted of endarterectomy and closure 
of the external carotid stump, which contained thrombotic 
material compatible with a source for emboli, with no 
subsequent episodes of visual or other neurologic difficul- 
ties. As an example of (2) above, a patient experienced a 
stroke 31/2 days after carotid endarterectomy associated 
with external carotid artery occlusion and extension o'f 
platelet-rich t rombus into the patent common carotid and 
internal carotid arteries, with embolization from it to the 
middle cerebral artery. 
An occluded external carotid artery after carotid 
endarterectomy ay represent a potential source for either 
chronic embolization or a site for extended thrombosis and 
embolization i  the acute situation. In the latter instance, 
it may he difficult to ascertain the relationship, if any, 
between thrombus in the occluded external carotid artery 
and thrombus in the common and internal carotid arteries. 
The fine case report, which documents a use for transcranial 
Doppler scanning, also calls attention to a potential 
problem from an acutely occluded external carotid artery. 
Robert L. Hew#t, MD 
Department of Surgery 
Tulane University School of Medicine 
1430 Tulane Ave. 
New Orleans, LA 70112 
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Reply 
To the Editors: 
We thank Dr. Hewitt for his interest in our case report, 
and his point regarding the potential importance of 
thrombus occluding the external carotid artery (ECA) is 
well made. In our case, thrombus was found on the 
endarterectomy surface in the internal carotid artery (ICA) 
separate from the origin of the ECA. Thrombus was not 
found to extend from the ECA to the ICA, neither was 
thrombus projecting from the ECA into the ICA or 
common carotid artery. Therefore we concluded that 
thrombus had formed at the two sites independently. 
However, the main point of our article was to highlight 
the ability of transcranial Doppler monitoring to provide 
direct evidence of particulate mbolization to the territory 
of the middle cerebral artery from whatever source. The 
original site of thrornbus formation may not be as 
important as the fact that the thrombus gives rise to 
significant embolization or results in a critical reduction in 
middle cerebral artery blood flow. Transcranial Doppler 
monitoring provides the surgeon with real-time vidence of 
both these parameters, enabling early reexploration of the 
artery, correction of the defect, and therefore the potential 
for preventing or minimizing neurologic deficits from this 
infrequent but often serious postoperative complication. 
Michael E. Gaunt, FRCS 
Department of Surgery 
Clinical Sciences Building 
Leicester Royal Infirmary 
Leicester LE2 7LX, United Kingdom 
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Clinical trials a must 
To the Editors: 
The year 1991 was a landmark in vascular surgery. The 
North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) 1 and the European Carotid Surgery Trial 
(ECST) 2 were completed and yielded clear evidence that 
carotid endarterectomy was the optimal treatment in 
patients with symptoms of carotid artery stenosis of 70% 
or greater of arterial diameter. Now, the news of the early 
completion of the Asymptomatic Carotid Atherosclerosis 
Study (ACAS) heralds another advance in our understand- 
ing of carotid artery disease. But even more important than 
the results of these trials is the fact that randomized, 
prospective, multicenter t ials were applied to a vascular 
surgical problem. Never before has such an approach to a 
vascular disorder been undertaken. 
The truth of the matter is that in the field of vascular 
surgery, investigation by clinical trials has lagged far 
behind other surgical subspeciakies. In particular, surgical 
oncologists have championed the clinical trial for decades. 
From the early trials of lumpectomy versus radical mas- 
tectomy 3 to the present day trials of cancer immnno- 
therapy, oncologists have long understood the power of 
the clinical trial. It is time for the vascular community 
to follow suit. 
For the most part, the NASCET, ECST, and ACAS 
trials have concluded. Now is not the time for con- 
gratulating one another on a job well done. It is the time 
to take the momentum gained from these recent rials and 
to apply it to the many unanswered questions currently 
plaguing vascular surgery. As an example, one specific area 
that bears immediate investigation comes to mind. Re- 
cently, use of the "Taylor" anastomotic vein patch has 
become widespread. 4 Although I do not dispute the 
results of Taylor, s they represent a single-center and, for 
the most part, a single-surgeon experience. Although 
polytetrafluoroethylene with an anastomotic vein patch 
may be a useful adjunct to the more commonly used 
vascular conduits, the need for a multicenter trial is 
obvious. The application of this technique by the surgical 
community with expectations of a conduit panacea, how- 
ever, only reinforces the commonly held view of vascular 
surgery as an anecdotal science. A clinical trial exploring 
the utility of such a novel and attractive conduit would 
require only a fraction of the effort involved in organizing 
the carotid artery trials. Although this is a single example, 
I dare say it would take little time to sight several more 
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areas in which clinical trials would be applicable. Only 
if vascular surgeons remain focused on the need for such 
investigations will real, meaningful data be forthcoming. 
Clearly, the results of the NASCET, ECST, and ACAS 
studies are powerful and will, without question, change the 
way vascular surgeons treat carotid artery disease. Let us 
not forget, however, that the true triumph of these 
investigations was the involvement of the vascular surgery 
community in randomized, prospective, multicenter clini- 
cal trials. 
John Ligush, Jr., MD 
Department ofVascular Surgery 
Campus Box 7212 
Burnett-Womack Clinical Sciences Building 
University of North Carolina 
Chapel Hill, NC 27599-7212 
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